



Correspondence: Authors' reply to Critical appraisal of "Goetz G, Wernly B, Wild C (2023) Wearable cardioverter defibrillator for preventing sudden cardiac death in patients at risk: An updated systematic review of comparative effectiveness and safety. IJC Heart & Vasculature 45 (2023) 101189" by M. Nürnberg, F. Semrau

Claudia Wild^{a,*}, Gregor Götz^a, Bernhard Wernly^b

^a Austrian Institute for Health Technology Assessment (AIHTA), Austria

^b Department of Internal Medicine, General Hospital Oberndorf, Teaching Hospital of the Paracelsus Medical University Salzburg, and Institute of General Practice, Family Medicine and Preventive Medicine, Paracelsus Medical University, Salzburg, Austria

Correspondence

Authors' reply to Nürnberg and Semrau

Nürnberg and Semrau question the validity of our systematic review [1]. We respectfully disagree with their claim of errors [2].

First, our conclusion is based on the only available randomised controlled trial (RCT). In this trial, the pre-defined null hypothesis of no treatment effect (h0) could not be rejected [3].

Second, we are not convinced that we should have used our chosen methods or reported on the available evidence differently. We have addressed the non-statistical trend towards improvement of depression scores [4] in patients with a WCD. Although in disagreement, we acknowledge that Nürnberg and Semrau judge our risk of bias (RoB) scaling (IHE-20 checklist [5]) as unbalanced. Single-arm trials are, per se, of very limited value when assessing comparative effectiveness [6]. Regarding GRADE [7], it is correct that the certainty of endpoints should be evaluated separately, which is also the case in our assessment. Respective judgements on the endpoint level can be found within the footnotes. Subsequent per-protocol and other post-hoc analyses [8] are included in our review. However, we focused on the primary analysis of VEST [3] within our GRADE assessment as the effect of assignment to intervention [9] was assessed in our SR.

Third, it is essential to clarify that we did not accuse any researchers of academic misconduct: VEST [3] was methodologically strong, but had strengths and limitations. RoB concerning arrhythmic mortality was judged to be high due to "deviations from intended intervention" (low compliance), following the Cochrane RoB algorithm [10]. Further ratings (D4: we found no red flags, but upholding blinding was considered

highly complex; D5: some secondary outcomes planned in the study protocol were not reported in currently available peer-reviewed publications) of some concerns were not causal for up- or downgrading the overall RoB for any of the endpoints.

We want to stress that the efficacy of a treatment is not the same as the comparative effectiveness of a treatment strategy. In post-MI patients, the WCD is part of a treatment strategy evaluated in the only available RCT [3], which did not demonstrate a statistically significant reduction in their primary endpoint arrhythmic mortality.

Fourth, the SR by Masri et al. [11] included 28 studies, while the SR by Aidelsburger et al. [12] included 46 studies. Both SRs had similar inclusion and exclusion criteria and used the same search period. Hence, it is reasonable to believe that Aidelsburger et al. [12] counted publications instead of studies (e.g., WEARIT-II). Of note, a recent HTA from Wales (HTW) came to similar conclusions as we did [13].

We acknowledge different opinions on the utility of the WCD for most high-risk patients among cardiologists [14,15]. We believe evidence from both sides has been presented to allow the medical community to form their own judgments.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

* Corresponding author at: HTA Austria - Austrian Institute for Health Technology Assessment GmbH, Garnisongasse 7/20, Mezzanin, 1090 Wien, Austria.
E-mail address: claudia.wild@aihta.at (C. Wild).

References

- [1] G. Goetz, B. Wernly, Wearable cardioverter-defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest, Update 2022, Decision Support Document 103/ 2. Update 2022: 2022 [cited 24.10.2022], Available from: <https://eprints.aihta.at/1407/>.
- [2] M. Nürnberg, F. Semrau, Critical appraisal of “Goetz G, Wernly B, Wild C (2023) Wearable cardioverter defibrillator for preventing sudden cardiac death in patients at risk: An updated systematic review of comparative effectiveness and safety. IJC Heart & Vasculature 45 (2023) 101189”, Int. J. Cardiol. Heart Vasc. 48 (2023) 101258, Epub 20230830, doi: 10.1016/j.ijcha.2023.101258.
- [3] J.E. Olgin, M.J. Pletcher, E. Vittinghoff, J. Wrancicz, R. Malik, D.P. Morin, et al., Wearable cardioverter-defibrillator after myocardial infarction, N. Engl. J. Med. 379(13) (2018) 1205–1215, doi: 10.1056/NEJMoa1800781, Epub 2018/10/04.
- [4] M. Weiss, G. Michels, F. Eberhardt, W. Fehske, S. Winter, F. Baer, et al., Anxiety, depression and quality of life in acute high risk cardiac disease patients eligible for wearable cardioverter defibrillator: Results from the prospective multicenter CRED-registry, PLoS One 14(3) (2019) e0213261, doi: 10.1371/journal.pone.0213261, Epub 2019/03/12.
- [5] Institute of Health Economics (IHE), Quality Appraisal Checklist for Case Series, 2016 [cited 01.07.2022], Available from: <https://www.ihe.ca/research-programs/rmd/cssqac/cssqac-about>.
- [6] European Network for Health Technology Assessment (EUnetHTA), D4.6 Validity of clinical studies, 2022 [cited 01.03.2023], Available from: <https://www.eunetha.eu/wp-content/uploads/2022/12/EUnetHTA-21-D4.6-Practical-Guideline-on-validity-of-clinical-studies-v1.0-1.pdf>.
- [7] G. Guyatt, A.D. Oxman, E.A. Akl, R. Kunz, G. Vist, J. Brozek, et al., GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables, J. Clin. Epidemiol. 64(4) (2011) 383–394, doi: 10.1016/j.jclinepi.2010.04.026, Epub 2011/01/05.
- [8] J.E. Olgin, B.K. Lee, E. Vittinghoff, D.P. Morin, S. Zweibel, E. Rashba, et al., Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: as-treated and per-protocol analyses, J. Cardiovasc. Electrophysiol. 31(5) (2020) 1009–1018, doi: 10.1111/jce.14404, Epub 2020/02/23.
- [9] J.P.T. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M.J. Page, et al., Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022), 2022, Available from: www.training.cochrane.org/handbook.
- [10] J.A.C. Sterne, J. Savović, M.J. Page, R.G. Elbers, N.S. Blencowe, I. Boutron, et al., RoB 2: a revised tool for assessing risk of bias in randomised trials, Bmj 366 (2019) 14898, doi: 10.1136/bmj.14898, Epub 2019/08/30.
- [11] A. Masri, A.M. Altibi, S. Erqou, M.A. Zmaili, A. Saleh, R. Al-Adham, et al., Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death: a systematic review and meta-analysis, JACC Clin. Electrophysiol. 5(2) (2019) 152–161, doi: 10.1016/j.jacep.2018.11.011, Epub 2019/02/21.
- [12] P. Aidselburger, J. Seyed-Ghaemi, C. Guinin, A. Fach, Effectiveness, efficacy, and safety of wearable cardioverter-defibrillators in the treatment of sudden cardiac arrest – results from a health technology assessment, Int. J. Technol. Assess. Health Care 36(4) (2020) 363–371, doi: 10.1017/S0266462320000379, Epub 2020/06/30.
- [13] Health Technology Wales (HTW), Wearable cardioverter-defibrillators for adults at high risk of sudden cardiac death, 2023 [cited 11.09.2023], Available from: <https://healthtechnology.wales/reports-guidance/wearable-cardioverter-defibrillators/>.
- [14] A.G. Bhatt, S. Mittal, The wearable cardioverter-defibrillator is not needed for most high-risk patients, Heart Rhythm O2 1(3) (2020) 230–233, doi: 10.1016/j.hroo.2020.07.002, Epub 20200714.
- [15] B.K. Lee, The wearable cardioverter-defibrillator is needed for most high-risk patients, Heart Rhythm O2 1(3) (2020) 227–229, doi: 10.1016/j.hroo.2020.07.001, Epub 20200714.